Article from the Miami Herald curated by Contributing Editor George Lundberg, MD, who notes:
The RenovoCath chemotherapy device permits targeted delivery of usual chemotherapy drugs directly into, and limited to, localized but inoperable pancreatic cancers. It is currently being tested in a phase 3 clinical trial.
.